Celltrion USA

Celltrion USA products

• Avtozma®

  • Generic: tocilizumab

  • Indication: interleukin-6 inhibitor used in inflammatory diseases

• Inflectra®

  • Generic: infliximab-dyyb

  • Indication: TNF-α inhibitor for immune-mediated diseases

• Osenvelt®

  • Generic: denosumab-bmwo

  • Indication: prevents skeletal-related events in bone metastases and giant cell tumor of bone; treats hypercalcemia of malignancy

• Osencilta? (if present—presumed similar to Osenvelt, please clarify)

• Omyclo® (assuming OMLYCLO®)

  • Generic: omalizumab-igec

  • Indication: anti-IgE therapy, primarily for severe asthma

• Steqeyma®

  • Generic: ustekinumab-stba

  • Indication: interleukin inhibitor for psoriasis and related conditions

• Stoboclo®

  • Generic: denosumab-bmwo (alternative dosage/indication set)

  • Indication: osteoporosis and bone loss prevention (various high-risk groups)

• Truxima®

  • Generic: rituximab-abbs

  • Indication: CD20-targeted therapy for B-cell malignancies and autoimmune disorders

• Vegzelma®

  • Generic: bevacizumab-adcd

  • Indication: VEGF inhibitor for several cancers (e.g., colorectal, lung, glioblastoma, kidney, cervical, ovarian)

• Yuflyma®

  • Generic: adalimumab-aaty

  • Indication: TNF-α inhibitor for a broad array of autoimmune inflammatory conditions

• Zymfentra®

• Generic: infliximab-dyyb (subcutaneous)

• Indication: maintenance treatment for moderately to severely active Crohn’s disease and ulcerative colitis via subcutaneous injection